van Ingen J, Griffith DE, Aksamit TR, Wagner D (2012d)
Pulmonary diseases caused by non-tuberculous
mycobacteria. Eur Respir Monogr 58:25–37
Wallace RJ Jr, Swenson JM, Silcox VA, Bullen MG
(1985) Treatment of nonpulmonary infections due to
Mycobacterium fortuitum and Mycobacterium
cheloneion the basis of in vitro susceptibilities. J
Infect Dis 152:500–514
Wallace RJ Jr, Drunbar D, Brown BA, Onyi G, Dunlap R,
Ahn CH, Murphy DT (1994) Rifampin-resistant
Mycobacterium kansasii. Clin Infect Dis 18:736–743
Wallace RJ Jr, Brown BA, Griffith DE, Girard WM,
Murphy DT (1996) Clarithromycin regimens for pul-
monaryMycobacterium aviumcomplex. The first
50 patients. Am J Respir Crit Care Med
153:1766–1772
Wallace RJ Jr, Brown-Elliott BA, McNulty S, Philley JV,
Killingley J, Wilson RW, York DS, Shepherd S,
Griffith DE (2014) Macrolide/azalide therapy for nod-
ular/bronchiectaticMycobacterium aviumcomplex
lung disease. Chest 146:276–282
Winthrop KL, Chang E, Yamashita S, Iademarco MF,
LoBue PA (2009) Non-tuberculous mycobacteria
infections and anti-tumor necrosis-αtherapy. Emerg
Infect Dis 15:1556–1561
Winthrop KL, McNelley E, Kendall B, Marshall-Olson A,
Morris C, Cassidy M, Saulson A, Hedberg K (2010)
Pulmonary nontuberculous mycobacterial disease
prevalence and clinical features: an emerging public
health disease. Am J Respir Crit Care Med
182:977–982Non-Tuberculous Mycobacteria: Classification, Diagnostics, and Therapy 25